



#15/B

ATTORNEY DOCKET NO. UCSF.002.01US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: **Vishwanath R. Lingappa, et al.**) Examiner: Winkler, Ulrike
Serial No.: **10/040,206**) Art Unit: 1648
Filed: **January 2, 2002**)
For: **HIV Capsid Assembly-Associated**) **MARKED UP VERSION OF**
Compositions and Methods) **CLAIMS**

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

RECEIVED
APR 15 2003
TECH CENTER 1600/2900

The Examiner is respectfully requested to make the following amendments. A clean copy of the text of the claims following the amendments is attached hereto

IN THE CLAIMS:

Cancel Claims 1-11 and 15-50 without prejudice to renewal as drawn to a non-elected invention.

12. (amended) A method of producing monoclonal antibodies [to] with conformational specificity for a [conformer of a] host chaperone protein that is involved in assembly of immature HIV capsids and not to conformers of said host chaperone protein that do not bind to Gag and do not facilitate HIV capsid assembly, said method comprising the steps of: *the*

CERTIFICATE OF FIRST CLASS MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231:

April 4, 2003
(Date)
Carrie Bucher
(Signature)
Carrie Bucher
(Printed Name)

immunizing knockout mice with [a] said host chaperone protein, wherein said knockout mice have a non-functional gene that no longer codes for said [conformers] host chaperone protein and lack the ability to produce said host chaperone protein;

producing hybridoma cells from [splens] antibody producing cells of said mice;

screening said hybridoma cells for production of antibodies to [both a native and a denatured conformer of] said host chaperone protein; and

propagating hybridoma cells producing antibodies [that bind substantially specifically to] with conformational specificity for said host chaperone protein [and not to conformers of said host chaperone protein that do not bind Gag and do not facilitate HIV capsid assembly], whereby antibodies to [native and denatured] said host chaperone protein [or peptide conformer of interest] are produced.

13. (reiterated) Monoclonal antibodies produced according to the method of Claim 12.

14. (reiterated) Binding fragments to said conformer derived from monoclonal antibodies produced according to the method of Claim 12.

Add the following new Claims.

--51. (new) The method according to Claim 12, wherein said host chaperone protein is HP68 and said conformer is an RNase L inhibitor.

B² 52. (new) The method according to Claim 12, wherein said host chaperone protein is obtained by separating a capsid intermediate complex into components comprising said host chaperone protein and an HIV capsid protein.

53. (new) The method according to Claim 52, wherein said capsid intermediate complex is selected from the group consisting of proteins having a buoyant density of about 10S, about 80S, about 150S and about 500S.--

PATENT

ATTORNEY DOCKET NO. UCSF.002.01US

Respectfully submitted,

Date: April 4, 2003

A handwritten signature in black ink, appearing to read "Barbara Rae-Venter", written over a horizontal line.

Barbara Rae-Venter, Ph.D.
Reg. No. 32,750

Rae-Venter Law Group, P.C.
PO Box 1898
Monterey, CA 93942-1898
Phone: (831) 648-3090
Facsimile: (831) 242-0137

BRV/mnb
Enclosure